
First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525
Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked T-cell engager (TCE) that targets epidermal growth factor receptor (EGFR). This trial marks a step in developing …